Last reviewed · How we verify
Aspirin maintenance dose
At a glance
| Generic name | Aspirin maintenance dose |
|---|---|
| Also known as | Aspirin, ASA |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer (PHASE3)
- Efficacy and Safety of Tirofiban for Patients With BAD (BRANT) (PHASE3)
- A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects (PHASE1)
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study (PHASE4)
- ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion (PHASE4)
- Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin maintenance dose CI brief — competitive landscape report
- Aspirin maintenance dose updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI